APO Research
Talk to an analyst

APO RESEARCH · REPORT

AI in Respiratory Diseases

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global AI in Respiratory Diseases Market Outlook and Growth Opportunities 2026

4 July 2026193 pages

Choose your research edition.

Industry ResearchAI in Respiratory Diseases Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal AI in Respiratory Diseases Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal AI in Respiratory Diseases Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal AI in Respiratory Diseases Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal AI in Respiratory Diseases Market Analysis and Forecast 2026-2032172 pages · $4,950 USD

Market perspective

The global AI in Respiratory Diseases market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for AI in Respiratory Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for AI in Respiratory Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for AI in Respiratory Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the AI in Respiratory Diseases market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the AI in Respiratory Diseases market include ArtiQ, Philips Healthcare, GE Healthcare, Siemens Healthineers, Swaasa AI, THIRONA, DeepMind Health, Verily and VIDA Diagnostics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global AI in Respiratory Diseases market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of AI in Respiratory Diseases and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents AI in Respiratory Diseases revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global AI in Respiratory Diseases market.

AI in Respiratory Diseases Segment by Company

ArtiQ

Philips Healthcare

GE Healthcare

Siemens Healthineers

Swaasa AI

THIRONA

DeepMind Health

Verily

VIDA Diagnostics Inc

Icometrix

Infervision

PneumoWave

Respiray

Dectrocel Healthcare

Zynnon

AI in Respiratory Diseases Segment by Type

Pulmonary Infection

MRI

CT Scan

AI in Respiratory Diseases Segment by Application

Hospital

Diagnostic Centers

Ambulatory Surgical Centers

Others

AI in Respiratory Diseases Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global AI in Respiratory Diseases status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the AI in Respiratory Diseases key companies, revenue, market share, and recent developments.

3. To split the AI in Respiratory Diseases breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions AI in Respiratory Diseases market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify AI in Respiratory Diseases significant trends, drivers, influence factors in global and regions.

6. To analyze AI in Respiratory Diseases competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI in Respiratory Diseases market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of AI in Respiratory Diseases and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI in Respiratory Diseases.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global AI in Respiratory Diseases industry.

Chapter 3: Detailed analysis of AI in Respiratory Diseases company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of AI in Respiratory Diseases in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of AI in Respiratory Diseases in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. AI in Respiratory Diseases Industry Trends Table 2. AI in Respiratory Diseases Industry Drivers Table 3. AI in Respiratory Diseases Industry Opportunities and Challenges Table 4. AI in Respiratory Diseases Industry Restraints Table 5. Global AI in Respiratory Diseases Revenue by Company (US$ Million) & (2021-2026) Table 6. Global AI in Respiratory Diseases Revenue Share by Company (2021-2026) Table 7. Global AI in Respiratory Diseases Company Ranking, (2024-2026) & (US$ Million) Table 8. Global AI in Respiratory Diseases Key Company Manufacturing Base & Headquarters Table 9. Global AI in Respiratory Diseases Company, Product Type & Application Table 10. Global AI in Respiratory Diseases Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global AI in Respiratory Diseases by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Pulmonary Infection Table 15. Significant Companies of MRI Table 16. Significant Companies of CT Scan Table 17. Global AI in Respiratory Diseases Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global AI in Respiratory Diseases Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global AI in Respiratory Diseases Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global AI in Respiratory Diseases Sales Value Share by Type (2021-2026) Table 21. Global AI in Respiratory Diseases Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Table 23. Significant Companies of Diagnostic Centers Table 24. Significant Companies of Ambulatory Surgical Centers Table 25. Significant Companies of Others Table 26. Global AI in Respiratory Diseases Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global AI in Respiratory Diseases Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global AI in Respiratory Diseases Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global AI in Respiratory Diseases Sales Value Share by Application (2021-2026) Table 30. Global AI in Respiratory Diseases Sales Value Share by Application (2027-2032) Table 31. Global AI in Respiratory Diseases Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global AI in Respiratory Diseases Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global AI in Respiratory Diseases Sales Value Share by Region (2021-2026) Table 34. Global AI in Respiratory Diseases Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global AI in Respiratory Diseases Sales Value Share by Region (2027-2032) Table 36. Global AI in Respiratory Diseases Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global AI in Respiratory Diseases Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global AI in Respiratory Diseases Sales Value Market Share by Country (2021-2026) Table 39. Global AI in Respiratory Diseases Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global AI in Respiratory Diseases Sales Value Market Share by Country (2027-2032) Table 41. ArtiQ Company Information Table 42. ArtiQ Business Overview Table 43. ArtiQ AI in Respiratory Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. ArtiQ AI in Respiratory Diseases Product Portfolio Table 45. ArtiQ Recent Development Table 46. Philips Healthcare Company Information Table 47. Philips Healthcare Business Overview Table 48. Philips Healthcare AI in Respiratory Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Philips Healthcare AI in Respiratory Diseases Product Portfolio Table 50. Philips Healthcare Recent Development Table 51. GE Healthcare Company Information Table 52. GE Healthcare Business Overview Table 53. GE Healthcare AI in Respiratory Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. GE Healthcare AI in Respiratory Diseases Product Portfolio Table 55. GE Healthcare Recent Development Table 56. Siemens Healthineers Company Information Table 57. Siemens Healthineers Business Overview Table 58. Siemens Healthineers AI in Respiratory Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Siemens Healthineers AI in Respiratory Diseases Product Portfolio Table 60. Siemens Healthineers Recent Development Table 61. Swaasa AI Company Information Table 62. Swaasa AI Business Overview Table 63. Swaasa AI AI in Respiratory Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Swaasa AI AI in Respiratory Diseases Product Portfolio Table 65. Swaasa AI Recent Development Table 66. THIRONA Company Information Table 67. THIRONA Business Overview Table 68. THIRONA AI in Respiratory Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. THIRONA AI in Respiratory Diseases Product Portfolio Table 70. THIRONA Recent Development Table 71. DeepMind Health Company Information Table 72. DeepMind Health Business Overview Table 73. DeepMind Health AI in Respiratory Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. DeepMind Health AI in Respiratory Diseases Product Portfolio Table 75. DeepMind Health Recent Development Table 76. Verily Company Information Table 77. Verily Business Overview Table 78. Verily AI in Respiratory Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Verily AI in Respiratory Diseases Product Portfolio Table 80. Verily Recent Development Table 81. VIDA Diagnostics Inc Company Information Table 82. VIDA Diagnostics Inc Business Overview Table 83. VIDA Diagnostics Inc AI in Respiratory Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. VIDA Diagnostics Inc AI in Respiratory Diseases Product Portfolio Table 85. VIDA Diagnostics Inc Recent Development Table 86. Icometrix Company Information Table 87. Icometrix Business Overview Table 88. Icometrix AI in Respiratory Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Icometrix AI in Respiratory Diseases Product Portfolio Table 90. Icometrix Recent Development Table 91. Infervision Company Information Table 92. Infervision Business Overview Table 93. Infervision AI in Respiratory Diseases Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Infervision AI in Respiratory Diseases Product Portfolio Table 95. Infervision Recent Development Table 96. PneumoWave Company Information Table 97. PneumoWave Business Overview Table 98. PneumoWave AI in Respiratory Diseases Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. PneumoWave AI in Respiratory Diseases Product Portfolio Table 100. PneumoWave Recent Development Table 101. Respiray Company Information Table 102. Respiray Business Overview Table 103. Respiray AI in Respiratory Diseases Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Respiray AI in Respiratory Diseases Product Portfolio Table 105. Respiray Recent Development Table 106. Dectrocel Healthcare Company Information Table 107. Dectrocel Healthcare Business Overview Table 108. Dectrocel Healthcare AI in Respiratory Diseases Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Dectrocel Healthcare AI in Respiratory Diseases Product Portfolio Table 110. Dectrocel Healthcare Recent Development Table 111. Zynnon Company Information Table 112. Zynnon Business Overview Table 113. Zynnon AI in Respiratory Diseases Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Zynnon AI in Respiratory Diseases Product Portfolio Table 115. Zynnon Recent Development Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. AI in Respiratory Diseases Product Image Figure 2. Global AI in Respiratory Diseases Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global AI in Respiratory Diseases Market Size (2021-2032) & (US$ Million) Figure 4. Global AI in Respiratory Diseases Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Pulmonary Infection Image Figure 8. MRI Image Figure 9. CT Scan Image Figure 10. Global AI in Respiratory Diseases Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global AI in Respiratory Diseases Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global AI in Respiratory Diseases Sales Value Share by Type (2021-2032) Figure 13. Hospital Image Figure 14. Diagnostic Centers Image Figure 15. Ambulatory Surgical Centers Image Figure 16. Others Image Figure 17. Global AI in Respiratory Diseases Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global AI in Respiratory Diseases Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global AI in Respiratory Diseases Sales Value Share by Application (2021-2032) Figure 20. Global AI in Respiratory Diseases Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global AI in Respiratory Diseases Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America AI in Respiratory Diseases Sales Value (2021-2032) & (US$ Million) Figure 23. North America AI in Respiratory Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe AI in Respiratory Diseases Sales Value (2021-2032) & (US$ Million) Figure 25. Europe AI in Respiratory Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific AI in Respiratory Diseases Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific AI in Respiratory Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America AI in Respiratory Diseases Sales Value (2021-2032) & (US$ Million) Figure 29. South America AI in Respiratory Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa AI in Respiratory Diseases Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa AI in Respiratory Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt AI in Respiratory Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Pulmonary Infection
  • MRI
  • CT Scan
Applications
  • Hospital
  • Diagnostic Centers
  • Ambulatory Surgical Centers
  • Others
Companies covered
  • ArtiQ
  • Philips Healthcare
  • GE Healthcare
  • Siemens Healthineers
  • Swaasa AI
  • THIRONA
  • DeepMind Health
  • Verily
  • VIDA Diagnostics Inc
  • Icometrix
  • Infervision
  • PneumoWave
  • Respiray
  • Dectrocel Healthcare
  • Zynnon

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global AI in Respiratory Diseases Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global AI in Respiratory Diseases Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 AI in Respiratory Diseases Market Dynamics
  1. 2.1 AI in Respiratory Diseases Industry Trends
  2. 2.2 AI in Respiratory Diseases Industry Drivers
  3. 2.3 AI in Respiratory Diseases Industry Opportunities and Challenges
  4. 2.4 AI in Respiratory Diseases Industry Restraints
3 AI in Respiratory Diseases Market by Company
  1. 3.1 Global AI in Respiratory Diseases Company Revenue Ranking in 2025
  2. 3.2 Global AI in Respiratory Diseases Revenue by Company (2021-2026)
  3. 3.3 Global AI in Respiratory Diseases Company Ranking (2024-2026)
  4. 3.4 Global AI in Respiratory Diseases Company Manufacturing Base and Headquarters
  5. 3.5 Global AI in Respiratory Diseases Company Product Type and Application
  6. 3.6 Global AI in Respiratory Diseases Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global AI in Respiratory Diseases Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 AI in Respiratory Diseases Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 AI in Respiratory Diseases Market by Type
  1. 4.1 AI in Respiratory Diseases Type Introduction
  2. 4.1.1 Pulmonary Infection
  3. 4.1.2 MRI
  4. 4.1.3 CT Scan
  5. 4.2 Global AI in Respiratory Diseases Sales Value by Type
  6. 4.2.1 Global AI in Respiratory Diseases Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global AI in Respiratory Diseases Sales Value by Type (2021-2032)
  8. 4.2.3 Global AI in Respiratory Diseases Sales Value Share by Type (2021-2032)
5 AI in Respiratory Diseases Market by Application
  1. 5.1 AI in Respiratory Diseases Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Diagnostic Centers
  4. 5.1.3 Ambulatory Surgical Centers
  5. 5.1.4 Others
  6. 5.2 Global AI in Respiratory Diseases Sales Value by Application
  7. 5.2.1 Global AI in Respiratory Diseases Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global AI in Respiratory Diseases Sales Value by Application (2021-2032)
  9. 5.2.3 Global AI in Respiratory Diseases Sales Value Share by Application (2021-2032)
6 AI in Respiratory Diseases Regional Value Analysis
  1. 6.1 Global AI in Respiratory Diseases Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global AI in Respiratory Diseases Sales Value by Region (2021-2032)
  3. 6.2.1 Global AI in Respiratory Diseases Sales Value by Region: 2021-2026
  4. 6.2.2 Global AI in Respiratory Diseases Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America AI in Respiratory Diseases Sales Value (2021-2032)
  7. 6.3.2 North America AI in Respiratory Diseases Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe AI in Respiratory Diseases Sales Value (2021-2032)
  10. 6.4.2 Europe AI in Respiratory Diseases Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific AI in Respiratory Diseases Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific AI in Respiratory Diseases Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America AI in Respiratory Diseases Sales Value (2021-2032)
  16. 6.6.2 South America AI in Respiratory Diseases Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa AI in Respiratory Diseases Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa AI in Respiratory Diseases Sales Value Share by Country, 2025 VS 2032
7 AI in Respiratory Diseases Country-level Value Analysis
  1. 7.1 Global AI in Respiratory Diseases Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global AI in Respiratory Diseases Sales Value by Country (2021-2032)
  3. 7.2.1 Global AI in Respiratory Diseases Sales Value by Country (2021-2026)
  4. 7.2.2 Global AI in Respiratory Diseases Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt AI in Respiratory Diseases Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt AI in Respiratory Diseases Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt AI in Respiratory Diseases Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ArtiQ
  2. 8.1.1 ArtiQ Company Information
  3. 8.1.2 ArtiQ Business Overview
  4. 8.1.3 ArtiQ AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  5. 8.1.4 ArtiQ AI in Respiratory Diseases Product Portfolio
  6. 8.1.5 ArtiQ Recent Developments
  7. 8.2 Philips Healthcare
  8. 8.2.1 Philips Healthcare Company Information
  9. 8.2.2 Philips Healthcare Business Overview
  10. 8.2.3 Philips Healthcare AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Philips Healthcare AI in Respiratory Diseases Product Portfolio
  12. 8.2.5 Philips Healthcare Recent Developments
  13. 8.3 GE Healthcare
  14. 8.3.1 GE Healthcare Company Information
  15. 8.3.2 GE Healthcare Business Overview
  16. 8.3.3 GE Healthcare AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GE Healthcare AI in Respiratory Diseases Product Portfolio
  18. 8.3.5 GE Healthcare Recent Developments
  19. 8.4 Siemens Healthineers
  20. 8.4.1 Siemens Healthineers Company Information
  21. 8.4.2 Siemens Healthineers Business Overview
  22. 8.4.3 Siemens Healthineers AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Siemens Healthineers AI in Respiratory Diseases Product Portfolio
  24. 8.4.5 Siemens Healthineers Recent Developments
  25. 8.5 Swaasa AI
  26. 8.5.1 Swaasa AI Company Information
  27. 8.5.2 Swaasa AI Business Overview
  28. 8.5.3 Swaasa AI AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Swaasa AI AI in Respiratory Diseases Product Portfolio
  30. 8.5.5 Swaasa AI Recent Developments
  31. 8.6 THIRONA
  32. 8.6.1 THIRONA Company Information
  33. 8.6.2 THIRONA Business Overview
  34. 8.6.3 THIRONA AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  35. 8.6.4 THIRONA AI in Respiratory Diseases Product Portfolio
  36. 8.6.5 THIRONA Recent Developments
  37. 8.7 DeepMind Health
  38. 8.7.1 DeepMind Health Company Information
  39. 8.7.2 DeepMind Health Business Overview
  40. 8.7.3 DeepMind Health AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  41. 8.7.4 DeepMind Health AI in Respiratory Diseases Product Portfolio
  42. 8.7.5 DeepMind Health Recent Developments
  43. 8.8 Verily
  44. 8.8.1 Verily Company Information
  45. 8.8.2 Verily Business Overview
  46. 8.8.3 Verily AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Verily AI in Respiratory Diseases Product Portfolio
  48. 8.8.5 Verily Recent Developments
  49. 8.9 VIDA Diagnostics Inc
  50. 8.9.1 VIDA Diagnostics Inc Company Information
  51. 8.9.2 VIDA Diagnostics Inc Business Overview
  52. 8.9.3 VIDA Diagnostics Inc AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  53. 8.9.4 VIDA Diagnostics Inc AI in Respiratory Diseases Product Portfolio
  54. 8.9.5 VIDA Diagnostics Inc Recent Developments
  55. 8.10 Icometrix
  56. 8.10.1 Icometrix Company Information
  57. 8.10.2 Icometrix Business Overview
  58. 8.10.3 Icometrix AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Icometrix AI in Respiratory Diseases Product Portfolio
  60. 8.10.5 Icometrix Recent Developments
  61. 8.11 Infervision
  62. 8.11.1 Infervision Company Information
  63. 8.11.2 Infervision Business Overview
  64. 8.11.3 Infervision AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Infervision AI in Respiratory Diseases Product Portfolio
  66. 8.11.5 Infervision Recent Developments
  67. 8.12 PneumoWave
  68. 8.12.1 PneumoWave Company Information
  69. 8.12.2 PneumoWave Business Overview
  70. 8.12.3 PneumoWave AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  71. 8.12.4 PneumoWave AI in Respiratory Diseases Product Portfolio
  72. 8.12.5 PneumoWave Recent Developments
  73. 8.13 Respiray
  74. 8.13.1 Respiray Company Information
  75. 8.13.2 Respiray Business Overview
  76. 8.13.3 Respiray AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Respiray AI in Respiratory Diseases Product Portfolio
  78. 8.13.5 Respiray Recent Developments
  79. 8.14 Dectrocel Healthcare
  80. 8.14.1 Dectrocel Healthcare Company Information
  81. 8.14.2 Dectrocel Healthcare Business Overview
  82. 8.14.3 Dectrocel Healthcare AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Dectrocel Healthcare AI in Respiratory Diseases Product Portfolio
  84. 8.14.5 Dectrocel Healthcare Recent Developments
  85. 8.15 Zynnon
  86. 8.15.1 Zynnon Company Information
  87. 8.15.2 Zynnon Business Overview
  88. 8.15.3 Zynnon AI in Respiratory Diseases Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Zynnon AI in Respiratory Diseases Product Portfolio
  90. 8.15.5 Zynnon Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst